[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369047-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369047-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","idr-induced-car-condensation-improves-the-cytotoxicity-of-car-ts-against-low-antigen-cancers","IDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers","","Chimeric antigen receptor (CAR)-T cell therapies show strong efficacy for otherwise hard-to-treat cancers, but approved CAR-Ts are constrained by low antigen sensitivity, limiting activity against tumors with low antigen expression. Researchers engineered CD19, CD22, and HER2 CARs incorporating intrinsically disordered regions (IDRs) to promote signaling condensation. CARs fused with IDRs from FUS, EWS, or TAF15 enhanced CAR-T target conjugation, increased synapse mechanical strength, boosted cytotoxic factor release, and improved killing of low-antigen cells in vitro, with further antitumor effects across blood and solid tumor models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/idr-induced-car-condensation-improves-the-cytotoxicity-of-car-ts-against-low-antigen-cancers/369047/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/idr-induced-car-condensation-improves-the-cytotoxicity-of-car-ts-against-low-antigen-cancers/369047.png","ImageObject",300,407,{"name":42,"@type":43},"CatatanPagi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem limits current clinically approved CAR-T therapies?","Question",{"text":63,"@type":64},"Current CAR-T therapies are limited by low antigen sensitivity, which reduces efficacy against cancers with low antigen expression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study modify CARs to improve function against low-antigen tumors?",{"text":68,"@type":64},"The researchers engineered CARs targeting CD19, CD22, and HER2 by including intrinsically disordered regions (IDRs) that promote signaling condensation.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key effects of IDR-fused CAR-Ts compared with conventional CAR-Ts?",{"text":72,"@type":64},"IDR-fused CAR-Ts promoted target conjugation, strengthened CAR-T synapses, increased release of cytotoxic factors, and enhanced killing of low-antigen-expressing cancer cells in vitro, with improved antitumor effects in blood and solid tumor models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369047,1790577657,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":97,"preview_urls":146},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Nat Chem Biol. Author manuscript; available in PMC 2026 January 23. |\n| --- | --- |\n\nPublished in final edited form as:  \nNat Chem Biol. 2026 March ; 22(3): 379–391. doi:10.1038/s41589-025-02031-x.  \nIDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers  \nXinyan Zhang 1 , Qian Xiao 1,8 , Longhui Zeng 1 , Fawzaan Hashmi 1,2 , Kazuki Sato 1 , Tobias Max Philipp Hartwich3 , Miranda Mansolf3 , Yang Yang-Hartwich3 , Xiaolei Su 1,4,5,6,7  \n1 Department of Cell Biology, Yale School of Medicine, New Haven, CT, USA.  \n2Yale College, New Haven, CT, USA.  \n3 Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA.  \n4Yale Cancer Center, New Haven, CT, USA.  \n5Yale Center for Immuno-Oncology, New Haven, CT, USA.  \n6Yale Center for systems and Engineering Immunology, New Haven, CT, USA.  \n7Yale Stem Cell Center, New Haven, CT, USA.  \n8 Present address: Institute of Modern Biology, Nanjing University, Nanjing, China.  \nAbstract  \nChimeric antigen receptor (CAR)-T cell therapies have shown remarkable efficacies for treating otherwise intractable cancers. However, current clinically approved CAR-T therapies are limited by low antigen sensitivity, impeding their efficacy against cancers with low antigen expression.  \nHere, to address this issue, we engineered CARs targeting CD19, CD22 and HER2 by including intrinsically disordered regions (IDRs) that promote signaling condensation. We discovered that the CAR fused with an IDR from FUS, EWS or TAF15 promoted the formation of CAR-T conjugation with cancer targets, the mechanical strength of CAR-T synapses and membrane-  \nOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.Reprints)[.](http://creativecommons.org/licenses/by/4.0/.Reprints)[Reprints](http://creativecommons.org/licenses/by/4.0/.Reprints) and permissions information is available [at](at www.nature.com/)[ www.nature.com/](at www.nature.com/)[ ](at www.nature.com/)[reprints](reprints.)[.](reprints.)  \nCorrespondence and requests for materials should be addressed to Xiaolei [Su. Xiaolei.su@yale.edu](Su. Xiaolei.su@yale.edu).  \nAuthor contributions  \nThe project was conceptualized by X.Z. and X.S. X.Z., Q.X., L.Z., F.H., K.S., T.H. and M.M. conducted the experiments and performed data analysis. X.S. and Y.Y-H. obtained funding support. X.S. supervised the project. X.Z. and X.S. wrote the paper withinput from all other authors.  \nCompeting interests  \nX.S. and X.Z. are coapplicants for a patent based on this work. The other authors declare no competing interests.  \nReporting summary  \nFurther information on research design is available in the Nature Portfolio Reporting Summary linked to this article. Additional information  \nExtended data is available for this paper at [https://doi.org/10.1038/s41589-025-02031-x](https://doi.org/10.1038/s41589-025-02031-x).  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nZhang et al. Page 2  \nproximal signaling, which led to an increased rel","cbCaiivvISRgeHqa","https://ap.wps.com/l/cbCaiivvISRgeHqa","pdf",7523256,45,"English","# Abstract\n## Core challenge: low antigen sensitivity\n## Engineering strategy: IDR-containing CARs\n## Observed outcomes: conjugation, synapses, killing\n## In vivo relevance and safety notes","[{\"question\":\"What problem limits current clinically approved CAR-T therapies?\",\"answer\":\"Current CAR-T therapies are limited by low antigen sensitivity, which reduces efficacy against cancers with low antigen expression.\"},{\"question\":\"How did the study modify CARs to improve function against low-antigen tumors?\",\"answer\":\"The researchers engineered CARs targeting CD19, CD22, and HER2 by including intrinsically disordered regions (IDRs) that promote signaling condensation.\"},{\"question\":\"What were the key effects of IDR-fused CAR-Ts compared with conventional CAR-Ts?\",\"answer\":\"IDR-fused CAR-Ts promoted target conjugation, strengthened CAR-T synapses, increased release of cytotoxic factors, and enhanced killing of low-antigen-expressing cancer cells in vitro, with improved antitumor effects in blood and solid tumor models.\"}]","IDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers | PDF",1790180354,113,[147,151,155,159,163],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/409fcda8ca3d0e59ba3bd0ff68851cad.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f9030d0242c0ad361800beb340b1df5.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df43e5e0015a9a44799ee6a60e7be42c.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e09e0835d4923a2121f517c1e18bde42.webp",980,1268,{"page_no":97,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5f06cbfdf169d26aa122646841b669c.webp",979,1267]